# A Study of ABT-301 Plus Tislelizumab With Bevacizumab in pMMR/Non-MSI-H Locally Advanced or mCRC

Source: https://onco.cc/trials/nct07244705/  
OnCo record `nct07244705` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of ABT-301, Tislelizumab, Bevacizumab in colorectal cancer, run by Anbogen Therapeutics, Inc., now recruiting.

## Summary

A Study of ABT-301 Plus Tislelizumab With Bevacizumab in pMMR/Non-MSI-H Locally Advanced or mCRC is a phase 1/2 interventional study registered as NCT07244705 by Anbogen Therapeutics, Inc., with 66 participants planned, started 2025-11 and due to reach its primary completion in 2028-04. Interventions recorded: ABT-301, Tislelizumab, Bevacizumab (Avastin). Conditions listed: Colorectal Cancer (Diagnosis), Colorectal Cancer Metastatic, Colorectal Cancer (CRC), Immunotherapy. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT07244705
- Phase: 1/2
- Setting: An Open-label, Multicenter, Phase 1/2 Study Exploring the Safety and Efficacy of ABT-301 in Combination With Tislelizumab and Bevacizumab in Participants With Proficient Mismatch Repair (pMMR)/Non-Microsatellite Instability-High (Non-MSI-H) Locally Advanced or Metastatic Colorectal Cancer (mCRC)
- Sponsor: Anbogen Therapeutics, Inc.
- Enrolled: 66

## Sources

- ClinicalTrials.gov NCT07244705: https://clinicaltrials.gov/study/NCT07244705

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/)
- drugs: [ABT-301](https://onco.cc/drugs/abt-301/), [Bevacizumab](https://onco.cc/drugs/bevacizumab/), [Tislelizumab](https://onco.cc/drugs/tislelizumab/)

---
JSON: https://onco.cc/api/v1/entities/nct07244705.json